Aralez Pharmaceuticals AstraZeneca Toprol-XL Acquisition 2016

Aralez Pharmaceuticals announced the acquisition of US rights to Toprol-XL and its authorized generic from AstraZeneca in October 2016, alongside YOSPRALA commercialization progress. The $175 million acquisition aims to accelerate profitability by adding substantial cardiovascular revenue and supporting product launches including ZONTIVITY re-launch and YOSPRALA commercialization with 110 trained sales representatives.